Skip to main content
Log in

Avoid cobicistat/elvitegravir-based regimens during pregnancy

  • Correspondence
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. Genvoya = cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Stribild = elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Tybost = cobicistat

  2. IMPAACT = International Maternal Pediatric Adolescent AIDS Clinical Trials

  3. Also see Reactions 1709 p1; 803331590

Reference

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Avoid cobicistat/elvitegravir-based regimens during pregnancy. Reactions Weekly 1748, 1 (2019). https://doi.org/10.1007/s40278-019-59917-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-59917-0

Navigation